72 results
8-K
EX-10.1
BVS
Bioventus Inc - Ordinary Shares
9 Jun 23
Departure of Directors or Certain Officers
5:04pm
, retirement or disability or any other specified termination of Continuous Service.
025851.0014-3541477v4
(e)Deferral of Award Payment. The Administrator … determination that the Participant’s Continuous Service has been terminated for Cause for the purposes of this Plan.
16.No Effect on Retirement and Other
8-K
BVS
Bioventus Inc - Ordinary Shares
29 Jun 22
Departure of Directors or Certain Officers
5:00pm
”), and the Company agreed on a transition plan providing for Mr. Nosenzo’s retirement from the Company, effective October 1, 2022. In connection with Mr … . Nosenzo’s retirement, the Company has decided not to replace the Chief Commercial Officer role. Instead, Mr. Nosenzo’s current sales management
S-8
EX-99.7
BVS
Bioventus Inc - Ordinary Shares
29 Oct 21
Registration of securities for employees
4:51pm
, but if and only if such Award does not vest prior to the date the individual first becomes an Employee.
“ERISA” means the Employee Retirement Income … an Option or a Stock Award under this Plan.
“Plan” means this MISONIX, INC. 2005 Equity lncentive Plan, as amended from time to time.
“Retirement” means
S-8
EX-99.4
BVS
Bioventus Inc - Ordinary Shares
29 Oct 21
Registration of securities for employees
4:51pm
the Employee Retirement Income Security Act of 1974, as amended from time to time, or any successor statute or statutes thereto. Reference to any specific Act … to time.
“Retirement” means retirement, as determined by the Committee in its sole discretion. Such term shall be applicable only to Participants who
S-8
EX-99.6
zkkmt
29 Oct 21
Registration of securities for employees
4:51pm
S-8
EX-99.5
1gr8ebc
29 Oct 21
Registration of securities for employees
4:51pm
8-K
EX-99.1
ythdd hw1rx0vy
9 Nov 21
Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance
7:35am
8-K
EX-99.1
ltxfuwe0y5241vyu
10 Mar 22
Bioventus Reports Fourth Quarter and Introduces Full Year 2022 Financial Guidance
7:34am
8-K
EX-99.1
lhw2ud
29 Mar 21
Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance
12:00am
S-8
EX-99.3
nar9 sbifk41b
29 Oct 21
Registration of securities for employees
4:51pm
DRS/A
EX-10.44
faaobcgnnlu4roh7zm
10 Nov 20
Draft registration statement (amended)
12:00am
8-K
EX-99.1
fcuigiwna0busci59t
26 Apr 22
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA
9:12am